AU2001266242A1 - Pharmaceutical compositions for the treatment of depression or symptoms suggesting depression - Google Patents

Pharmaceutical compositions for the treatment of depression or symptoms suggesting depression

Info

Publication number
AU2001266242A1
AU2001266242A1 AU2001266242A AU6624201A AU2001266242A1 AU 2001266242 A1 AU2001266242 A1 AU 2001266242A1 AU 2001266242 A AU2001266242 A AU 2001266242A AU 6624201 A AU6624201 A AU 6624201A AU 2001266242 A1 AU2001266242 A1 AU 2001266242A1
Authority
AU
Australia
Prior art keywords
depression
treatment
pharmaceutical compositions
symptoms suggesting
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001266242A
Inventor
Peter Kovacs
Anna Racz
Csilla Varga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Vegyeszeti Gyar Nyrt
Original Assignee
Richter Gedeon Vegyeszeti Gyar RT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Vegyeszeti Gyar RT filed Critical Richter Gedeon Vegyeszeti Gyar RT
Publication of AU2001266242A1 publication Critical patent/AU2001266242A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

The invention relates to the human therapeutic application of famotidine or its therapeutically acceptable salts for the treatment of depression or symptoms suggesting depression, including somatic depression, unipolar depression, functional diseases of psychic origin, atypical depression, dysthymia, bipolar affective disorders, seasonal depression and persistent mood disorder. The invention also relates to such application of a pharmaceutical composition and its manufacturing.
AU2001266242A 2000-06-06 2001-06-06 Pharmaceutical compositions for the treatment of depression or symptoms suggesting depression Abandoned AU2001266242A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU0002154 2000-06-06
HU0002154A HUP0002154A3 (en) 2000-06-06 2000-06-06 Use of famotidine for the preparation of pharmaceutical compositions treating depression or symptoms related with depression
PCT/HU2001/000065 WO2001093863A2 (en) 2000-06-06 2001-06-06 Pharmaceutical compositions for the treatment of depression or symptoms suggesting depression

Publications (1)

Publication Number Publication Date
AU2001266242A1 true AU2001266242A1 (en) 2001-12-17

Family

ID=89978380

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001266242A Abandoned AU2001266242A1 (en) 2000-06-06 2001-06-06 Pharmaceutical compositions for the treatment of depression or symptoms suggesting depression

Country Status (10)

Country Link
US (1) US20040010021A1 (en)
EP (1) EP1289520B1 (en)
JP (1) JP2003535133A (en)
AT (1) ATE302000T1 (en)
AU (1) AU2001266242A1 (en)
DE (1) DE60112750T2 (en)
DK (1) DK1289520T3 (en)
ES (1) ES2247137T3 (en)
HU (1) HUP0002154A3 (en)
WO (1) WO2001093863A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8058296B2 (en) * 2008-11-25 2011-11-15 Richard Tokunaga Treatment and prevention of deleterious effects associated with alcohol consumption
JP6284490B2 (en) 2012-12-28 2018-02-28 株式会社新日本科学 OCT3 activity inhibitor or OCT3 detector comprising an imidazopyridine derivative as an active ingredient
WO2015002150A1 (en) 2013-07-03 2015-01-08 株式会社新日本科学 Novel compound, organic cation transporter 3 detection agent, and organic cation transporter 3 activity inhibitor
WO2015163832A1 (en) 2014-04-25 2015-10-29 Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. An ibuprofen and famotidine combined composition having improved stability

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5460825A (en) * 1990-05-23 1995-10-24 Mcneil-Ppc, Inc. Taste mask coatings for preparing chewable pharmaceutical tablets
US5352688A (en) * 1991-02-14 1994-10-04 The Mount Sinai School Of Medicine Of The City University Of New York Methods for the treatment of bradyphrenia in parkinson's disease
WO1995001780A1 (en) * 1993-07-06 1995-01-19 Merck & Co., Inc. H2 antagonist-alginate combinations
WO1995001784A1 (en) * 1993-07-06 1995-01-19 Merck & Co., Inc. H2 antagonist-sucralfate-antiflatulent combinations

Also Published As

Publication number Publication date
WO2001093863A2 (en) 2001-12-13
JP2003535133A (en) 2003-11-25
DE60112750D1 (en) 2005-09-22
US20040010021A1 (en) 2004-01-15
DE60112750T2 (en) 2006-06-08
HU0002154D0 (en) 2000-08-28
HUP0002154A3 (en) 2002-06-28
DK1289520T3 (en) 2005-10-17
ES2247137T3 (en) 2006-03-01
ATE302000T1 (en) 2005-09-15
EP1289520A2 (en) 2003-03-12
HUP0002154A2 (en) 2002-04-29
WO2001093863A3 (en) 2002-05-02
EP1289520B1 (en) 2005-08-17

Similar Documents

Publication Publication Date Title
CY1116215T1 (en) Combination therapy for the therapeutic treatment of Protein Deficiency Disorders
EA200701296A1 (en) 3,5-Disposable and 3,5,7-triple-substituted 3H-oxazolo-and 3H-thiazolo [4,5-D] pyrimidin-2-she and their medicines
ATE506059T1 (en) THERAPY TO TREAT OVERACTIVE BLADDER
DE60331537D1 (en) COMBINATIONS FOR THE TREATMENT OF MULTIPLE MYELOMA
ATE450269T1 (en) PEPTIDE PYYÄ3-36Ü FOR THE TREATMENT OF METABOLIC DISEASES
AR026610A1 (en) A PIRROLIDINACETAMIDE DERIVATIVE ONLY OR IN COMBINATION FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
MX2009002893A (en) Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates.
MXPA02012272A (en) Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv.
CY1108932T1 (en) Compounds 4- (heterocyclyl) -benzenesulfoximine for the therapeutic treatment of inflammatory diseases
TW200611695A (en) Pyrrolopyridine derivatives
DE60320095D1 (en) COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES
TNSN06403A1 (en) 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
WO2001076555A3 (en) Lipid-based drug delivery systems for topical application
MX2023003678A (en) Hsd17b13 inhibitors and uses thereof.
MX2023003677A (en) Hsd17b13 inhibitors and uses thereof.
MX2023003675A (en) Hsd17b13 inhibitors and uses thereof.
DK1343472T3 (en) Thixotropic nasal spray
AU2001266242A1 (en) Pharmaceutical compositions for the treatment of depression or symptoms suggesting depression
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
EE200100689A (en) Use of IL6RIL6 Chimera for the preparation of a medicament for the treatment of neurological diseases, and pharmaceutical composition
BG105984A (en) Osanetant in the treatment of mood disorders
RU2013139704A (en) USE OF YB-1 PROTEIN AND ITS FRAGMENTS FOR THE PRODUCTION OF MEDICINES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
HUP0204180A2 (en) External composition and its use for treating of allergic skin diseases
DE602007009283D1 (en) EN AND YOUR USE
WO2000054770A8 (en) Pharmaceutical compositions comprising troponin subunits, fragments and homologs thereof and methods of their use to inhibit angiogenesis